MDAI

Spectral AI Announces 2024 First Quarter Financial Results

Retrieved on: 
화요일, 5월 7, 2024
Sale, FDA, Administration, ELOC, ASPR, PBS, Burn, SWAT, Human services, FY, DFU, Trial of the century, Artificial intelligence, Development, Assessment, MDAI, RCSI, Spectral, Patient, Acquisition, Health, Marketing, Ulcer, Clinical trial, Avita Medical, Growth, Pharmaceutical industry

DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2024 (“Q1 2024”) and provided an update on its ongoing business activities.

Key Points: 
  • DeepView AI®-Burn Devices Deployed in UK; Expect Commercial Revenue in 2H 2024
    DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2024 (“Q1 2024”) and provided an update on its ongoing business activities.
  • “During the first quarter we continued to execute against our strategic priorities resulting in significant accomplishments across the enterprise,” said Peter M. Carlson, CEO of Spectral AI.
  • Completed enrollment in our DFU training study in the US with expected completion of our DFU validation study in 2H 2024.
  • Additionally, Spectral AI entered into a fixed price standby equity purchase agreement (“SEPA”) with a long-only investor that includes a $12.5 million prepaid advance (“Advances”).

Spectral AI to Participate at the Sidoti Micro-Cap Virtual Investor Conference

Retrieved on: 
목요일, 5월 2, 2024
MDAI, Spectral, Conference, Artificial intelligence, Interest

DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that management is scheduled to present and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Investor Conference, taking place on May 8-9, 2024.

Key Points: 
  • DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that management is scheduled to present and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Investor Conference, taking place on May 8-9, 2024.
  • The Company’s presentation will begin at 12:15 pm ET on May 9, 2024 and can be accessed live here .
  • Interested parties may also access the live and archived webcast of the presentation by visiting the Investors section of Spectral AI’s website at https://investors.spectral-ai.com/news-events/events .
  • Registration is free and participants do not need to be a client of Sidoti & Company LLC.

Spectral AI Schedules 2024 First Quarter Financial Results and Conference Call

Retrieved on: 
수요일, 4월 24, 2024
MDAI, Artificial intelligence

DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after the close of the stock market.

Key Points: 
  • DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after the close of the stock market.
  • The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.
  • Investors interested in participating in the live call can dial:

Spectral AI Names Erich Spangenberg CEO of its IP Focused Subsidiary and Explores Potential Spin-Off of that Subsidiary

Retrieved on: 
수요일, 4월 24, 2024
IP, Investment, Publication, SIM, Partnership, Artificial intelligence, MDAI, Spectral, Acquisition, Committee, Partner

DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Erich Spangenberg has been appointed as the Chief Executive Officer of its health care IP-focused subsidiary, Spectral IP.

Key Points: 
  • DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Erich Spangenberg has been appointed as the Chief Executive Officer of its health care IP-focused subsidiary, Spectral IP.
  • “Spectral AI is fortunate that our largest shareholder, Erich Spangenberg, has agreed to assume the CEO role at Spectral IP.
  • Erich has consistently been recognized for his unrivaled track record in global IP investment, monetization, enforcement, acquisition, and licensing,” said Pete Carlson, CEO of Spectral AI.
  • As CEO of Spectral IP, Erich will report to me and to our Board as he prepares Spectral IP for a potential spin-off.”
    Erich Spangenberg stated, “I believe Spectral IP represents a significant opportunity to deliver additional value to Spectral AI shareholders.

Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer

Retrieved on: 
월요일, 4월 1, 2024
Burn, Brigham Young University, Avita Medical, MDAI, Business administration, Patient, Global strategy, Artificial intelligence, Spectral, Publication, Master of Business Administration, Health Economics, Johnson & Johnson, Allergan, Government, Physician, Medtech

DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer.

Key Points: 
  • DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer.
  • Jeremiah has more than 20 years of medical device marketing experience, including global marketing and business strategy.
  • Mr. Sparks will be responsible for both domestic and international product commercialization.
  • “We are thrilled to have Jeremiah join the company as we move towards commercialization of DeepView,” said Peter M. Carlson, CEO of Spectral AI.

Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
수요일, 3월 27, 2024
De novo, DFU, Diabetic foot ulcer, Certification, Burn, Government, Development, FY, MDAI, Patient, Research, History, Artificial intelligence, Classification, Sale, Standard of care, Human services, Research and development, Wound healing, Trial of the century, Clinical trial, ASPR, ISO, FDA, Administration, Food, Pharmaceutical industry

DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.

Key Points: 
  • DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.
  • “Spectral AI achieved much in 2023, and our progress along multiple fronts has continued into 2024,” said Peter M. Carlson, Chief Executive Officer.
  • “
    In September 2023, we were awarded the largest contract in our history from the US Government valued at up to $150.0 million.
  • All comparisons to Q4 2023 and FY 2023 are to the comparable periods ended December 31, 2022, unless otherwise stated.

Spectral AI Secures Access to $12.5 Million of New Equity Capital

Retrieved on: 
수요일, 3월 20, 2024
Burn, MDAI, Research, Ulcer, Artificial intelligence, Sale, Government agency, Spectral, Capital punishment

DALLAS, March 20, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has entered into a fixed price prepaid advance and standby equity purchase agreement (“SEPA”) with a long-only investor. Total capacity under the SEPA is $30.0 million, consisting of a prepaid advance of $12.5 million, $5.0 million of which was funded today with a fixed conversion price of $3.16. Any additional draws above the prepaid advances are at the sole discretion of the Company.

Key Points: 
  • Total capacity under the SEPA is $30.0 million, consisting of a prepaid advance of $12.5 million, $5.0 million of which was funded today with a fixed conversion price of $3.16.
  • Any additional draws above the prepaid advances are at the sole discretion of the Company.
  • “We are pleased to announce this equity funding as we pivot to commercialization while continuing our research and development activities,” said Peter M. Carlson, CEO of Spectral AI.
  • “Together with our non-dilutive funding from various U.S. Government agencies, this new equity-linked instrument supports our strategic imperatives.

Spectral AI Announces Receipt of $1 Million of Financing for Spectral IP, Inc., its Intellectual Property Subsidiary Focused on the Broader Artificial Intelligence Ecosystem

Retrieved on: 
화요일, 3월 19, 2024
MDAI, Patent, Intellectual property, Artificial intelligence, IP, AI, Spectral, Ecosystem, Medical device

DALLAS, March 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has received a $1 million investment from an affiliate of its largest shareholder into its recently formed subsidiary Spectral IP, Inc. (“Spectral IP”).

Key Points: 
  • DALLAS, March 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has received a $1 million investment from an affiliate of its largest shareholder into its recently formed subsidiary Spectral IP, Inc. (“Spectral IP”).
  • Spectral IP will focus on advancing intellectual property (IP) in the broader AI ecosystem through acquisitions, strategic partnerships and collaborations with AI technology providers, healthcare institutions, and research organizations to accelerate innovation and expand market reach.
  • Wensheng Fan, Spectral AI’s Chief Innovation Strategist, said, “Medical Device companies are not only focusing on innovation to enhance their patent portfolios but are also making strategic investments in AI.
  • The integration of Artificial Intelligence is increasing in the medical device industry, but still lags other industries in its adoption.

Spectral AI Schedules 2023 Fourth Quarter and Full Year Financial Results and Conference Call

Retrieved on: 
수요일, 3월 13, 2024
MDAI, Artificial intelligence

DALLAS, March 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, March 27, 2024 after the close of the stock market.

Key Points: 
  • DALLAS, March 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, March 27, 2024 after the close of the stock market.
  • The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.
  • Investors interested in participating in the live call can dial:

Spectral AI Announces New US Government Contract to Further Accelerate the Development of the Handheld Version of DeepView™ Wound Imaging System

Retrieved on: 
화요일, 3월 12, 2024
Government, DHA, Health, MDAI, Patient, Artificial intelligence, Spectral, Miniaturization, Defense, State, Medical device

The ultimate goal of the contract and this targeted non-dilutive funding is to optimize the functionality and size of the device and to ensure its combat readiness.

Key Points: 
  • The ultimate goal of the contract and this targeted non-dilutive funding is to optimize the functionality and size of the device and to ensure its combat readiness.
  • These optimizations will, in turn, increase the device’s potential for a portable, handheld version for home health care and related invaluable assistance to medical professionals in many settings.
  • “Spectral AI is proud to partner with DHA and the USAMMDA on this crucial initiative.
  • This award further validates Spectral AI’s technology and the importance of a battlefield burn solution we are focusing on,” stated Pete Carlson, CEO of Spectral AI.